Abstract
The objective of this study is to assess the safety and efficacy of repeated intra-articular injection of high molecular weight hyaluronic acid (LBSA0103) at a 26-week interval, in patients with osteoarthritis of the knee. The study was an open-label, single arm, multicentre prospective trial conducted in patients with symptomatic knee osteoarthritis. The intervention consisted of two intra-articular injections of LBSA0103, with the second injection performed 26 weeks after the first injection. The primary outcome was the incidence of adverse drug reactions related to each injection. Assessment of efficacy of repeated injections in terms of maintenance of pain relief was a secondary objective of this study. Of the 185 patients screened, 174 patients received the first injection and 153 patients received both injections of LBSA0103. Nine adverse drug reactions occurred in seven patients (4.02%) after the first injection, while only one adverse drug reaction occurred (0.65%) after the second injection. As a secondary outcome measure, the improvements in the efficacy parameters including total WOMAC score and weight-bearing pain were all significant at both week 13 and 39 compared to the baseline value (P < 0.001), and improvements after the second injection were consistent with those after the initial injection of LBSA0103 (between week 26 and week 39, P < 0.001). Repeated intra-articular injection of LBSA0103 at a 26-week interval is safe without increased risk of adverse drug reactions. Additionally, LBSA0103 is effective in reduction of osteoarthritis knee pain and in maintenance of pain reduction for a 39-week period when a second injection is administered.
Similar content being viewed by others
References
Bannuru RR, Natov NS, Dasi UR, Schmid CH, McAlindon TE (2011) Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis–meta-analysis. Osteoarthr Cartil 19(6):611–619
Bannuru RR, Natov NS, Obadan IE, Price LL, Schmid CH, McAlindon TE (2009) Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Arthritis Rheum 61(12):1704–1711
Lo GH, LaValley M, McAlindon T, Felson DT (2003) Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA 290(23):3115–3121
Modawal A, Ferrer M, Choi HK, Castle JA (2005) Hyaluronic acid injections relieve knee pain. J Fam Pract 54(9):758–767
Strauss EJ, Hart JA, Miller MD, Altman RD, Rosen JE (2009) Hyaluronic acid viscosupplementation and osteoarthritis: current uses and future directions. Am J Sports Med 37(8):1636–1644
Greenberg DD, Stoker A, Kane S, Cockrell M, Cook JL (2006) Biochemical effects of two different hyaluronic acid products in a co-culture model of osteoarthritis. Osteoarthr Cartil 14(8):814–822
Karna E, Miltyk W, Palka JA, Jarzabek K, Wolczynski S (2006) Hyaluronic acid counteracts interleukin-1-induced inhibition of collagen biosynthesis in cultured human chondrocytes. Pharmacol Res 54(4):275–281
Hunter DJ (2015) Viscosupplementation for osteoarthritis of the knee. N Engl J Med 372(11):1040–1047
Gomis A, Pawlak M, Balazs EA, Schmidt RF, Belmonte C (2004) Effects of different molecular weight elastoviscous hyaluronan solutions on articular nociceptive afferents. Arthritis Rheum 50(1):314–326
Navarro-Sarabia F, Coronel P, Collantes E et al (2011) A 40-month multicentre, randomised placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project. Ann Rheum Dis 70(11):1957–1962
Chevalier X, Jerosch J, Goupille P et al (2010) Single, intra-articular treatment with 6 ml hylan GF 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial. Ann Rheum Dis 69(01):113–119
Åkermark C, Berg P, Björkman A, Malm P (2002) Non-animal stabilised hyaluronic acid in the treatment of osteoarthritis of the knee. Clin Drug Investig 22(3):157–166
Kenne L, Gohil S, Nilsson EM et al (2013) Modification and cross-linking parameters in hyaluronic acid hydrogels—definitions and analytical methods. Carbohyd Polym 91(1):410–418
Boulle K, Glogau R, Kono T et al (2013) A review of the metabolism of 1, 4-butanediol diglycidyl ether-crosslinked hyaluronic acid dermal fillers. Dermatol Surg 39(12):1758–1766
Altman R, Asch E, Bloch D et al (1986) Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 29(8):1039–1049
Kellgren J, Lawrence J (1957) Radiological assessment of osteo-arthrosis. Ann Rheum Dis 16(4):494
Jüni P, Hari R, Rutjes AW (2015) Intra-articular corticosteroid for knee osteoarthritis. Cochrane Database Syst Rev 22(10):CD005328
Fauci AS, Dale DC, Balow JE (1976) Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med 84(3):304–315
Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW (1988) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15(12):1833–1840
Pham T, van der Heijde D, Altman R et al (2004) OMERACT-OARSI initiative: osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthr Cartil 12(5):389–399
Berenbaum F, Grifka J, Cazzaniga S et al (2012) A randomised, double-blind, controlled trial comparing two intra-articular hyaluronic acid preparations differing by their molecular weight in symptomatic knee osteoarthritis. Ann Rheum Dis 71(9):1454–1460
Larsen NE, Dursema H, Skrabut EM (2007) Clearance kinetics of a single injection crosslinked hylan-based viscosupplement in a rabbit model. Osteoarthr Cartil 15:C64
Pullman-Mooar S, Mooar P, Sieck M, Clayburne G, Schumacher HR (2002) Are there distinctive inflammatory flares after hylan gf 20 intraarticular injections? J Rheumatol 29(12):2611–2614
Goldberg VM, Coutts RD (2004) Pseudoseptic reactions to hylan viscosupplementation: diagnosis and treatment. Clin Orthop Relat Res 419:130–137
Leopold SS, Warme WJ, Pettis PD, Shott S (2002) Increased frequency of acute local reaction to intra-articular hylan GF-20 (synvisc) in patients receiving more than one course of treatment. J Bone Jt Surg Am 84(9):1619–1623
Zhang W, Robertson J, Jones A, Dieppe P, Doherty M (2008) The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis 67(12):1716–1723
Campbell J, Bellamy N, Gee T (2007) Differences between systematic reviews/meta-analyses of hyaluronic acid/hyaluronan/hylan in osteoarthritis of the knee. Osteoarthritis and cartilage 15(12):1424–1436
McAlindon TE, Bannuru RR (2012) Osteoarthritis: is viscosupplementation really so unsafe for knee OA? Nat Rev Rheumatol 8(11):635–636
Jørgensen A, Stengaard-Pedersen K, Simonsen O et al (2010) Intra-articular hyaluronan is without clinical effect in knee osteoarthritis: a multicentre, randomised, placebo-controlled, double-blind study of 337 patients followed for 1 year. Ann Rheum Dis. doi:10.1136/ard.2009.118042
Maheu E, Zaim M, Appelboom T et al (2010) Comparative efficacy and safety of two different molecular weight (MW) hyaluronans F60027 and Hylan G-F20 in symptomatic osteoarthritis of the knee (KOA). Results of a non inferiority, prospective, randomized, controlled trial. Clin Exp Rheumatol 29(3):527–535
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
All authors have no financial interests or personal relationships with people or organization that could have potentially and inappropriately influence the conduct or reporting of this work.
Ethics statement for human study
The institutional review board (IRB) of each hospital granted approval of the trial, and written consent approved by the Ministry of Food and Drug Safety in Korea as well as the IRB was obtained from each patient before initiation of the study.
Ethics statement for clinical trials
This is a clinical trial on the third phase, registered at the service of the US National Institutes of Health (ClinicalTrials.gov; http://www.clinicaltrials.gov), number NCT02122601.
Funding
This study was funded by LG Life Sciences. The funding sources had no role in the study design, collection, analysis or interpretation of the data, writing of the manuscript, or in the decision to submit the manuscript for publication.
Conflict of interest
All authors declare that they have no conflict of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Lee, J.K., Choi, CH., Oh, KJ. et al. Safety and efficacy of bi-annual intra-articular LBSA0103 injections in patients with knee osteoarthritis. Rheumatol Int 37, 1807–1815 (2017). https://doi.org/10.1007/s00296-017-3803-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-017-3803-5